Cryoport Inc.
Cryoport Inc.
11/12/2024 | Press release | Distributed by Public on 11/12/2024 16:31
Reflecting on 2024: A Year of Groundbreaking Achievements
Reflecting on 2024: A Year of Groundbreaking Achievements
As we close out 2024, we're reflecting on a year marked by transformative milestones and significant growth at Cryoport Systems. This year, we took bold strides to redefine the future of supply chain solutions for life sciences. Our journey has been defined by a commitment to our mission: Enabling the Outcome™ by empowering our clients to deliver life-changing therapies to patients worldwide and supporting individuals on their journey to grow their families through our specialized logistics services in reproductive medicine.
Rebranding for the Future: A Bold New Chapter
We kicked off 2024 with an exciting and strategic rebrand, aligning our identity with our expanding capabilities and evolving vision. On January 17, we unveiled our refreshed look at a momentous simulcast event, where Cryoport's CFO Robert Stefanovich rang the opening bell at NASDAQ in New York, while CEO Jerrell Shelton led a Fireside Chat on the main stage at Advanced Therapies (Phacilitate) in Miami. This event, streamed live, symbolized the seamless blend of Cryoport's rich legacy and forward-looking innovation as we embraced the next chapter in our journey.
At the heart of our rebrand is our new tagline: Enabling the Outcome™. This encapsulates our unwavering commitment to supporting our clients as they pioneer the next wave of therapeutic advancements and helping individuals achieve their dreams of growing their families through our specialized logistics services in reproductive medicine. From logistics excellence to comprehensive BioServices, biostorage, and IntegriCell™ cryopreservation services, Cryoport Systems now offers an integrated suite of solutions that ensures the safe, efficient, and seamless delivery of cutting-edge therapies. As we evolve, we remain deeply focused on delivering the breakthroughs of tomorrow, today.
Industry Recognition: Leading the Charge in Life Sciences Innovation
At Cryoport Systems, our team of industry-leading experts is at the core of our success. With decades of specialized experience across logistics, BioServices and biostorage, cryopreservation, and regulatory frameworks, we are trusted as innovators and thought leaders in the life sciences sector. Through contributions in supply chain innovation and unwavering support for next-generation advanced therapies, Cryoport Systems is shaping the future of the industry. Here's a look at how we've been recognized in 2024:
0% Failure Rate: Our Support of Certainty
In an article with gasworld, Cryoport Systems' CEO Mark Sawicki, Ph.D. discussed our ambitious goal of achieving a 0% failure rate in the complex world of life sciences logistics. He explained how Cryoport Systems' expansive platform of supply chain solutions is crucial to Enabling the Outcome™ for organizations managing sensitive materials and irreplaceable therapies. By setting the bar for reliability, Cryoport Systems is making the impossible, possible for our partners.
Cryoport Systems Talks Leveraging Supply Chain Visibility Technologies with Pharmaceutical Outsourcing
Mark Sawicki also authored a thought-leadership article in Pharmaceutical Outsourcing, where he explored the challenges of maintaining consistent temperatures during the transport of biopharmaceutical products. Highlighting the critical need for advanced visibility into supply chains, Mark discussed how these technologies are essential for ensuring the quality of personalized therapies that are increasingly integrated into complex manufacturing processes.
Cryoport Systems Receives 4 Nominations, 1 Award from APCGTEA
Cryoport Systems was thrilled to receive four prestigious nominations for the Asia Pacific Cell & Gene Therapy Excellence Awards (APCGTEA) 2024, winning in the category for Best Cryogenic Supplier Award - Biopreservation. The ACGTEA acknowledges outstanding achievements by innovators, researchers, and manufacturers who are pushing the boundaries in new therapies, R&D, and manufacturing. We are honored to be held in such esteem.
Cryoport Systems: Leading the Way in Quality and Commitment to Excellence
At Cryoport Systems, we are committed to managing risks while maintaining the highest standards of quality and excellence across all our operations. Our dedication is reflected in the recent MSCI ESG "A" rating of Cryoport, Inc., which highlights our continuous efforts to uphold superior product safety and quality, robust governance, and effective environmental and social practices.
Cryoport Systems Featured on Fierce Biotech Podcast: Pioneering Next-Generation Logistics Solutions for Gene Therapy
On the Fierce Biotech podcast, Cryoport Systems Senior Vice President, Mike Dybicz, and Director of Product Marketing, Khoa Tran, shared insights on our innovations in temperature-controlled logistics for the rapidly evolving gene therapy market. Their discussion emphasized how Cryoport Systems is anticipating future challenges while ensuring the precision and safety necessary for life-saving therapies.
Next-Generation Risk Mitigation in the Temperature-Controlled Supply Chain for Advanced Therapies with ISO 21973 Compliance
Cryoport Systems' expertise in transporting temperature-sensitive biologics is showcased in a newly published peer-reviewed article that explores how we are setting new standards for risk mitigation in advanced therapies. The article outlines our groundbreaking and proprietary technologies, including the Veri-Clean® cleaning protocol, Chain of Compliance® traceability system, and Cryoportal® logistics management platform. These tools are redefining the safe transport of therapeutic cells and empowering the scalability of life-saving treatments.
Poster Presentation: Development of an Automated Cryopreservation Process for Leukapheresis to Support CGT Supply Chain
At ISCT 2024, Cryoport Systems presented key insights on automating cryopreservation processes to support cell therapy manufacturing. Our poster on leukapheresis and the IntegriCell™ cryopreservation solution highlighted the potential of automated, closed processing to enhance cell viability and ensure consistency across multiple donor-derived leukopaks. This GMP-compatible solution promises to elevate the standard of care in cell therapy manufacturing.
Download the Poster and Watch the Video Presentation >>
Products & Services: Launching Transformative Solutions
In 2024, Cryoport Systems continued to set the standard in life sciences supply chain management with groundbreaking products and services tailored to the unique demands of cell and gene therapy. From redefining cryopreservation processes to unveiling advanced shipping and packaging systems, these launches reflect our commitment to enhancing reliability, scalability, and efficiency. Each innovation supports our mission to enable life-saving therapies and deliver transformative outcomes for patients worldwide.
IntegriCell™ Cryopreservation Services: Preserving the Future of Medicine
This year, we launched IntegriCell, an advanced platform designed to revolutionize cryopreservation for the cell and gene therapy supply chain. By integrating automated, closed-system processing with GMP-compatible practices, IntegriCell delivers unparalleled cell viability and batch-to-batch consistency for critical leukapheresis materials. This standardized solution reduces variability, supports scalability, and accelerates the development of life-saving therapies, ensuring that manufacturers can bring treatments to market with confidence.
Cryoport Elite® Ultra Cold Shipping System: Redefining Cold Chain Logistics
The Cryoport Elite® Ultra Cold Shipping System represents a leap forward in -60°C to -80°C dry ice transportation for sensitive biologics. Ideal for viral vectors and finished gene therapy products, this system combines unmatched durability with user-friendly features and cutting-edge risk-mitigating technology. By safeguarding the integrity of critical therapies during transit, the Cryoport Elite ensures seamless delivery, even under the most demanding conditions. This innovation is setting a new standard for ultra-cold logistics.
Cryoport Express® Cryogenic HV3 Shipping System: Future-Proofing Your Supply Chain
As compliance and regulatory landscapes evolve, the Cryoport Express® Cryogenic HV3 Shipping System is designed to keep you ahead of potential disruptions. Its next-generation design integrates advanced monitoring and risk mitigation features, ensuring secure transport of sensitive cryogenic payloads. Engineered for safety, efficiency, and mobility, the HV3 Shipping System also meets the latest airline shipping mandates, offering you peace of mind and uninterrupted operations in a rapidly changing regulatory environment.
Cryoport Safepak® System: Setting a New Standard for Payload Protection
The Safepak® System 1800 redefines secondary packaging for cryogenic shipments, combining innovative design with unmatched security and compliance. Built to shield payloads from vibration, shock, and catastrophic failure, the Safepak System ensures the safe transport of critical materials. Its intuitive, cost-efficient design simplifies packing processes, delivering an unparalleled level of protection for sensitive commodities. With the Safepak System, you can trust that your payloads are safeguarded at every step.
Expanding our Global Footprint
In 2024, Cryoport Systems made transformative strides to strengthen our global presence, enhancing our ability to support clients at the forefront of innovation. With facility launches and expansions in France, the UK, Belgium, and the United States, we have bolstered our infrastructure to deliver advanced logistics, cryopreservation, and BioServices solutions. These investments reflect our dedication to meeting the evolving needs of the life sciences industry while ensuring seamless, high-quality support across key regions worldwide.
Pont du Château, France : Expanding Capacity for European BioServices
Cryoport Systems enhanced its European operations with a significant expansion at our Pont-du-Château facility in France. This growth increases our capacity to provide high-quality BioServices, including biostorage and supply chain management, to clients across Europe. By expanding this critical hub, we're better equipped to support the needs of advanced therapy developers while ensuring seamless integration with our global network of temperature-controlled logistics solutions.
Read the News Release or see Highlights from the Ribbon Cutting >>
Stevenage, U.K. Global Supply Chain Hub: A Gateway to Innovation
The launch of our Stevenage Global Supply Chain Hub in the UK marked a major milestone in Cryoport Systems' mission to create localized solutions with global impact. Strategically located within one of Europe's leading life sciences ecosystems, this facility enhances our ability to provide specialized logistics services, including last-mile solutions like the Cryoshuttle®. The Stevenage hub reinforces our commitment to supporting Europe's growing cell and gene therapy market with exceptional service and innovative technology.
Read the News Release or see Highlights from the Facility Launch Event >>
Houston, TX Launch of IntegriCell™ Facility to Advance Cryopreservation Capabilities
Cryoport Systems introduced an expanded cryopreservation service offering in Houston, positioning the facility as a key facility for our IntegriCell™ solution. Equipped with state-of-the-art automated processing systems, the Houston site is dedicated to providing high-quality, standardized cryopreserved materials that meet the demanding needs of cell therapy manufacturing. This facility further strengthens our ability to deliver reliable and scalable cryopreservation solutions for clinical and commercial partners in the Americas and beyond.
Read the News Release or see Highlights from the Ribbon Cutting >>
IntegriCell™ Cryopreservation Center of Excellence Launches in Belgium
The launch of our Belgium facility underscores Cryoport Systems' commitment to expanding our footprint in Europe. As part of the IntegriCell™ solution, the Belgium site focuses on advancing cryopreservation services to ensure consistency and viability of cellular materials. This strategic addition complements our existing European infrastructure, providing seamless access to critical supply chain services for the region's growing cell and gene therapy sector.
Read the Press Release and Learn More about the Launch >>
Sharing Knowledge: Resources to Drive Success in Cell and Gene Therapy Supply Chains
At Cryoport Systems, we're more than logistics experts, we're educators, innovators, and partners in advancing cell and gene therapy. In 2024, we reaffirmed our commitment to sharing industry-leading insights through whitepapers, case studies, webinars, and articles. These resources address today's most pressing supply chain challenges, from compliance to scalability, providing actionable strategies to optimize your operations.
ISO 21973: How to Ensure Full Compliance Throughout Every Step of the Journey
Dive into our whitepaper on ISO 21973, which outlines strategies for achieving full compliance in transporting therapeutic cells. Learn how our proprietary Chain of Compliance® extends traceability, integrates advanced technologies, and safeguards therapy integrity during transit.
BioServices: Advanced Solutions for Cell and Gene Therapy Material Management
Uncover how Cryoport Systems' advanced BioServices streamline material management for cell and gene therapy (CGT) development. This whitepaper explores solutions for overcoming regulatory complexities and optimizing supply chains, ensuring product integrity and compliance.
From Risk to Regulatory Approval: How Cryoport Systems Validated a Shipping Solution, Enabling CGT Commercial Launch
See how Cryoport Systems addressed critical challenges by validating a shipping solution to support a major CGT commercial launch. Our innovative risk mitigation strategies ensured compliance and secured regulatory approval for this groundbreaking therapy.
Comprehensive Risk Mitigation for Viral Vector Logistics
Explore our Info Brief on ensuring the safe transport of viral vectors-critical components in gene therapy. Learn how Cryoport Systems' solutions safeguard materials with comprehensive monitoring and purpose-built shipping strategies.
Navigating Your Path to Globalization: Untangling the Regulatory Maze of the ATMP Supply Chain
Learn to streamline your Advanced Therapy Medicinal Products (ATMPs) supply chain with our expert insights. This Info Brief offers guidance on overcoming customs, compliance, and international regulatory challenges.
Webinar: Critical Supply Chain and Logistics Considerations for Cell and Gene Therapy Management
Join a thought-provoking discussion on the unique logistics and supply chain challenges in CGT, featuring Cryoport Systems' CEO and other industry experts. Learn how innovative solutions ensure product safety and efficiency.
Webinar: Breaking Through Supply Chain Bottlenecks in Cell & Gene Therapy
Discover strategies for overcoming common roadblocks in CGT supply chains, from managing variability to enhancing scalability. Learn best practices for streamlining operations and improving patient outcomes.
Webinar: When does outsourcing autologous collection center qualification and the cell therapy supply chain make sense?
Explore the pros and cons of outsourcing collection center qualification for CAR-T therapies. Gain insights from leading experts on optimizing logistics for efficiency and reliability.
Strategic Partnerships Fuel Cryoport Systems' Expanding Impact Across Cell & Gene Therapy and Beyond
Cryoport Systems continues to be the trusted partner of choice in 2024 for advancing life-saving therapies through strategic collaborations with leaders in cell and gene therapy, cryopreservation, and reproductive medicine. By partnering with renowned CDMOs like VGXI, SK Pharmetco, and Minaris Regenerative Medicine, as well as expanding cryopreservation capabilities through partnerships like those with NMDP (previously Be The Match BioTherapies) and Gulf Coast Regional Blood Center, and driving innovation in fertility solutions with TMRW Life Sciences, Cryoport Systems is further enabling the successful development and delivery of critical therapies. These partnerships reinforce our commitment to Enabling the Outcome™ through unparalleled expertise, advanced technologies, and comprehensive supply chain solutions.
Cryoport Systems and Minaris Regenerative Medicine Form Strategic Partnership to Support Advancement of Cell and Gene Therapies
Cryoport Systems and Minaris Regenerative Medicine have formed a strategic partnership aimed at providing the cell and gene therapy industry with fully integrated logistics and manufacturing services. Announced in June 2024, this collaboration combines Cryoport Systems' expertise in temperature-controlled logistics with Minaris' contract manufacturing capabilities for regenerative medicine products. The partnership will support biotechnology and pharmaceutical companies in advancing cell and gene therapies by offering seamless solutions, from cell collection and tissue processing to secure transport and delivery of critical products to patients. This collaboration reflects both companies' shared commitment to advancing healthcare and ensuring the safe and efficient delivery of life-saving therapies.
SK pharmteco and Cryoport Systems Partner for Cell and Gene Therapy Logistics and BioServices
Cryoport Systems and SK pharmteco have entered into a strategic partnership to provide integrated logistics and manufacturing services to the biotechnology and pharmaceutical industries. Announced in September 2024, this collaboration leverages Cryoport Systems' end-to-end supply chain solutions, which include biomaterial collection, shipping systems, data solutions, and BioServices, to support SK pharmteco's contract manufacturing of both small molecules and cell and gene therapy products. By combining their strengths, Cryoport Systems and SK pharmteco aim to deliver safe, efficient, and high-quality services, ensuring the integrity of these vital therapies and accelerating the global reach of life-saving treatments. This partnership underscores both companies' shared mission to advance healthcare and bring transformative therapies to patients worldwide.
VGXI Selects Cryoport Systems for Biostorage, Bioservices and Supply Chain Solutions to Advance Next-Generation Therapies
Cryoport Systems and VGXI, Inc., a subsidiary of GeneOne Life Science, have announced a strategic partnership aimed at advancing the development of next-generation therapies, including cell and gene therapies and mRNA-based treatments. The partnership, which began in October 2024, brings together VGXI's expertise in nucleic acid biopharmaceuticals and Cryoport Systems' end-to-end supply chain solutions, including biostorage, bioservices, and logistics. Cryoport Systems will support VGXI's manufacturing of plasmid DNA products, providing integrated services from its Houston facility to ensure the safe storage and transport of critical therapeutic materials. This collaboration strengthens both companies' commitment to delivering high-quality, lifesaving therapies to patients worldwide, supporting the continued growth of the cell and gene therapy sector.
Cryoport Systems and Gulf Coast Regional Blood Center Launch Strategic Alliance to Enhance Cellular Therapy Services
Cryoport Systems and Gulf Coast Regional Blood Center (GCRBC) have launched a strategic alliance aimed at enhancing the availability of high-quality, manufacture-ready cryopreserved allogeneic leukopaks for cellular therapy research, development, and treatment. This partnership, announced in October 2024, coincides with the grand opening of Cryoport Systems' state-of-the-art IntegriCell™ facility in Houston, Texas. By combining GCRBC's expertise in donor recruitment, management, and apheresis collection with Cryoport Systems' leading cryopreservation and biologistics capabilities, the partnership creates a seamless, end-to-end solution for the life sciences community. The collaboration strengthens the quality and consistency of cellular therapy products, supporting the development of lifesaving treatments for patients worldwide.
TMRW Life Sciences and Cryoport Systems Form Strategic Partnership to Elevate Standards for Frozen Egg, Embryo, and Sperm Offsite Storage and Biologistics
Cryoport Systems and TMRW Life Sciences have announced a strategic partnership to elevate standards in frozen egg, embryo, and sperm offsite storage and transport. This collaboration combines TMRW's cutting-edge automated specimen management technology with Cryoport Systems' proven expertise in temperature-controlled logistics to provide fertility clinics with secure, reliable, and efficient solutions for managing growing specimen inventories. The partnership leverages both companies' ISO certifications and advanced technologies, ensuring the highest standards of safety, security, and quality control for reproductive specimen management. Together, they offer clinics a seamless, end-to-end solution for specimen transport, storage, and data integrity, reinforcing the trust patients and clinics place in their services.
Looking Ahead: Building on a Year of Success and Innovation
As 2024 comes to a close, Cryoport Systems celebrates a year defined by transformative achievements, strategic growth, and unwavering dedication to advancing life sciences. From pioneering cryopreservation breakthroughs to expanding global capabilities and strengthening partnerships, we have solidified our position as a trusted partner in enabling the successful development and delivery of life-saving therapies. This year has been a testament to the power of innovation, collaboration, and our relentless commitment to excellence across cell and gene therapy, reproductive medicine, and animal health.
Looking to the future, Cryoport Systems remains steadfast in our mission to reshape the supply chain landscape for the life sciences. As we prepare for the opportunities and challenges of 2025, we are inspired by the lives we touch through our work and the partnerships that amplify our impact. Together with our clients, partners, and teams worldwide, we will continue to push the boundaries of what's possible, delivering solutions that transform lives and drive progress.
Join us in Enabling the Outcome™
Ready to partner with Cryoport Systems in 2025? Discover how our innovative solutions and expert services can support your mission to advance science and improve lives. Contact us today!